Trials / Completed
CompletedNCT05535972
To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD
A 12-week, Prospective, Open Label, Single Cohort Study to Evaluate the Real-world Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (Trelegy Ellipta) in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 463 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD. The secondary objective is to evaluate the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with symptomatic COPD. TRELEGY and ELLIPTA are trademarks of the GlaxoSmithKline group of companies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FF/UMEC/VI | FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta. |
Timeline
- Start date
- 2022-10-14
- Primary completion
- 2023-09-25
- Completion
- 2023-09-25
- First posted
- 2022-09-10
- Last updated
- 2025-12-11
- Results posted
- 2024-11-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05535972. Inclusion in this directory is not an endorsement.